We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Brimonidine as a possible treatment for myopia.
- Authors
Peng, Zixuan; Xiang, Aiqun; He, Hong; Luo, Yaqi; Wu, Shunliang; Luo, Yanting; Yang, Junming; Nie, Ke; Zhong, Xingwu
- Abstract
Background: Myopia is becoming a huge burden on the world's public health systems. The purpose of this study was to explore the effect of brimonidine in the treatment of form-deprivation myopia (FDM) and the relationship between intraocular pressure (IOP) and myopia development. Methods: Monocular form deprivation myopia (FDM) was induced in three-week-old pigmented male guinea pigs. They were treated with 3 different methods of brimonidine administration (eye drops, and subconjunctival or intravitreal injections). Four different concentrations of brimonidine were tested for each method (2µg/µL, 4µg/µL, 20µg/µL, and 40µg/µL). All treatments continued for a period of 21 days. Tonometry, retinoscopy, and A-scan ultrasonography were used to monitor intraocular pressure, refractive error and axial length (AL), respectively. Results: Treatment with subconjunctival brimonidine at 40µg/µL, and intravitreal brimonidine at 2µg/µL and 4µg/µL, inhibited the development of FDM. The myopic refraction, excessive axial length, and elevation of IOP were significantly decreased. Brimonidine in eye drops was ineffective. Conclusion: Brimonidine at appropriate doses significantly reduced the development of FD myopia in guinea pigs. The IOP may change with FD myopia.
- Subjects
MYOPIA; ORTHOKERATOLOGY; EYE drops; REFRACTIVE errors; INTRAVITREAL injections; GUINEA pigs
- Publication
BMC Ophthalmology, 2024, Vol 24, Issue 1, p1
- ISSN
1471-2415
- Publication type
Article
- DOI
10.1186/s12886-024-03433-6